Introduction {#S1}
============

The concept of an autonomous single immunoglobulin variable domain (single-domain antibodies or sdAbs) as the smallest representation of an antigen-binding-competent antibody was first described by Ward et al. in the mouse ([@B1]). With the discovery of naturally occurring heavy chain-only antibodies in *Camelidae* ([@B2]) and in cartilaginous sharks ([@B3]) several years later (the single variable domains of which can recognize antigen autonomously), it became clear that sdAbs represented not only a theoretical possibility but a viable immunological solution to the problem of antigen recognition. Although the human humoral immune system produces only conventional antibodies with paired heavy and light chains and not sdAbs, the question of whether human sdAbs (autonomous variable heavy- or light-chain domains, V~H~s or V~L~s) could be isolated and/or molecularly engineered *in vitro* was brought to light.

The identification, engineering and biophysical characterization of a handful of non-antigen-specific human V~H~/V~L~ sdAbs has been extensively reported and discussed ([@B4]). The first efforts to produce human V~H~/V~L~ sdAbs with novel antigen-binding specificities used "camelized" scaffolds that incorporated the solubilizing framework region (FR) substitutions found in camelid sdAbs ([@B5]--[@B9]). Although this approach yielded antigen-specific sdAbs with excellent solubility and biophysical properties, it relied on undesirable sequence deviation from the human IGHV germline. Later, rare fully human rearranged V~H~ and V~L~ variable domains were discovered that were autonomously stable and monomeric and large phage display libraries were constructed by randomizing their complementarity-determining regions (CDRs), although it was clear from the mid-2000s that certain CDR sequences (potentially low in hydrophobic content and rich in negative charge) were better compatible with solubility and stability of these molecules ([@B9]--[@B11]). There are now many examples of fully human antibodies (primarily V~H~s) isolated from such libraries against a variety of targets, including α-amylase ([@B12]), β-galactosidase ([@B13], [@B14]), *Candida albicans* MP65 and SAP-2 ([@B15]), carbonic anhydrase ([@B12]), CD154 ([@B16]), CD28 ([@B17]), CD40 ([@B18], [@B19]), CD40L ([@B20]), *Clostridium difficile* toxin B ([@B21]), EGFR ([@B22]), glypican-2 ([@B23]), glypican-3 ([@B24]), human serum albumin (HSA) ([@B25]--[@B27]), lysozyme ([@B28]--[@B30]), maltose-binding protein ([@B31]), MDM4 ([@B32]), mesothelin ([@B33]), TNF-α ([@B34]), TNFR1 ([@B35]), and VEGF ([@B22]). These fully human V~H~/V~L~ sdAbs exhibit a variety of antigen-binding modes and functional activities and several have entered clinical development, where they have been generally well-tolerated albeit unexpectedly immunogenic ([@B36], [@B37]).

Here, we report the design, construction and characterization of three novel phage-displayed, synthetically randomized human V~H~/V~L~ sdAb libraries. We attempted to circumvent the unfavorable biophysical properties of many human V~H~/V~L~ sdAbs by (i) selecting ultra-stable V~H~/V~L~ sdAbs tolerant to CDR modification as library scaffolds, (ii) maximizing randomized sequence diversity in CDRs using trinucleotide mutagenesis, and (iii) spiking the library with negatively charged residues to encourage solubility. Similarly to the experiences of others, we were able to isolate monomeric, high-affinity V~H~/V~L~ sdAbs from the libraries against some antigens but not against others. The stochastic process of selecting binders from human V~H~/V~L~ sdAb libraries is likely a consequence of fundamental tradeoffs between CDR sequence and human V~H~/V~L~ sdAb stability and aggregation resistance.

Materials and Methods {#S2}
=====================

Identification of Human Autonomous V~H~/V~L~ sdAb Scaffolds {#S2-1}
-----------------------------------------------------------

The human autonomous V~H~ and V~L~ sdAb scaffolds used in this study (Table [1](#T1){ref-type="table"}; Figure S1 in Supplementary Material) were isolated as previously described by To et al. ([@B38]) and Kim et al. ([@B39]). Disulfide-stabilized versions of each V~H~/V~L~ sdAb (bearing an intradomain disulfide linkage formed between Cys residues at IMGT positions 54 and 78) were produced by overlap extension PCR as described in Kim et al. ([@B40]).

###### 

Properties of human V~H~ and V~L~ single-domain antibody scaffolds used in this study.

  Type        Scaffold[^a^](#tfn1){ref-type="table-fn"}   Disulfide linkages[^b^](#tfn2){ref-type="table-fn"}   Germline rearrangement   CDR3 length (aa)   *T*~m~ (°C)   Monomer (%)   Reference
  ----------- ------------------------------------------- ----------------------------------------------------- ------------------------ ------------------ ------------- ------------- -----------
  V~L~        VL383                                       23--104                                               IGKV3-20--IGKJ2          9                  57.3          \>95          ([@B39])
  VL383~SS~   23--104, 54--78                             IGKV3-20--IGKJ2                                       9                        73.7               85.3                        
  VL382       23--104                                     IGKV3-20--IGKJ1                                       9                        70.1               \>95          ([@B39])      
  VL382~SS~   23--104, 54--78                             IGKV3-20--IGKJ1                                       9                        83.3               \>95                        
  VL335       23--104                                     IGKV3-20--IGKJ1                                       9                        61.7               \>95          ([@B39])      
  VL335~SS~   23--104, 54--78                             IGKV3-20--IGKJ1                                       9                        79.0               \>95          ([@B39])      
  VL330       23--104                                     IGKV1-39--IGKJ2                                       9                        62.8               \>95          ([@B39])      
  VL330~SS~   23--104, 54--78                             IGKV1-39--IGKJ2                                       9                        83.7               \>95                        
  VL325       23--104                                     IGKV3-11--IGKJ4                                       9                        68.5               \>95          ([@B39])      
  VL325~SS~   23--104, 54--78                             IGKV3-11--IGKJ4                                       9                        82.5               \>95          ([@B39])      
  V~H~        VH420                                       23--104                                               IGHV3-15--IGHJ4          10                 57.8          \>95          ([@B38])
  VH420~SS~   23--104, 54--78                             IGHV3-15--IGHJ4                                       10                       67.3               \>95                        
  VH428       23--104                                     IGHV3-49--IGHJ4                                       14                       62.3               \>95          ([@B38])      
  VH428~SS~   23--104, 54--78                             IGHV3-49--IGHJ4                                       14                       73.1               \>95                        
  VH429       23--104                                     IGHV3-23--IGHJ4                                       12                       58.5               \>95          ([@B38])      
  VH429~SS~   23--104, 54--78                             IGHV3-23--IGHJ4                                       12                       71.8               \>95                        
  VHB82       23--104                                     IGHV3-23--IGHJ6                                       6                        57.9               \>95          ([@B38])      
  VHB82~SS~   23--104, 54--78                             IGHV3-23--IGHJ6                                       6                        72.9               80.8                        
  VHM81       23--104                                     IGHV3-23--IGHJ3                                       14                       66.9               \>95          ([@B38])      
  VHM81~SS~   23--104, 54--78                             IGHV3-23--IGHJ3                                       14                       76.8               \>95                        

*^a^Full-length amino acid sequences are listed in Figure S1 in Supplementary Material*.

*^b^IMGT numbering*.

CDR Shuffling {#S2-2}
-------------

All three CDRs of each V~H~/V~L~ scaffold were simultaneously exchanged for those listed in Table [2](#T2){ref-type="table"} (20 V~H~/V~L~ scaffolds × 12 CDR sets = 240 CDR-shuffled variants). DNA constructs encoding the CDR-shuffled variants were synthesized commercially (GeneArt/Life Technologies, Regensberg, Germany) and subcloned into the pSJF2H bacterial expression vector ([@B12]).

###### 

Amino acid sequences of complementarity-determining region (CDR) sets introduced into human V~H~/V~L~ single-domain antibody (sdAb) scaffolds for biophysical stability assessment.

  V~L~ CDR set       CDR-L1[^a^](#tfn3){ref-type="table-fn"}       CDR-L2[^b^](#tfn4){ref-type="table-fn"}       CDR-L3[^c^](#tfn5){ref-type="table-fn"}       CDR-L3 length (aa)
  ------------------ --------------------------------------------- --------------------------------------------- --------------------------------------------- ------------------------
  1                  RASQSVLVHLA                                   GDSYRAD                                       QQTFYPST                                      8
  2                  RASQSVISNLA                                   GDSFRAF                                       QQVAHPTT                                      8
  3                  RASQSVTDTLLA                                  GISHRAD                                       QQLVHPFT                                      8
  4                  RASQSVVHNLA                                   GLSTRAH                                       QQFDHPYT                                      8
  5                  RASQSVSSNLA                                   GASLRAT                                       QQYLIPPAT                                     9
  6                  RASQSVAPSLLA                                  GTSTRAP                                       QQPTLFPTT                                     9
  7                  RASQSVNLPYLA                                  GVSTRAY                                       QQIAVTPYT                                     9
  8                  RASQSVDYNLA                                   DISFRAN                                       QQSLSPPAT                                     9
  9                  RASQSVNITSLA                                  GTSTRAD                                       QQTNTHHPVT                                    10
  10                 RASQSVSSYLA                                   GLSLRAV                                       QQTDSFFPFT                                    10
  11                 RASQSVPIVLA                                   GHSLRAD                                       QQLAFFDPFT                                    10
  12                 RASQSVYLNLA                                   GVSVRAD                                       QQILLFYPHT                                    10
                                                                                                                                                               
  **V~H~ CDR set**   **CDR-H1[^d^](#tfn6){ref-type="table-fn"}**   **CDR-H2[^e^](#tfn7){ref-type="table-fn"}**   **CDR-H3[^f^](#tfn8){ref-type="table-fn"}**   **CDR-H3 length (aa)**
  1                  SNAWMS                                        RITSKTDGGTTD                                  DQANAFDI                                      8
  2                  DGYAMH                                        VTNNGGSTS                                     QSITGPTGAFDI                                  12
  3                  SSYAMS                                        AISGGGDHTY                                    EGMVRGVSSAPFDY                                14
  4                  ISESMT                                        AISSSGGSTY                                    KKIDGARYDY                                    10
  5                  NTLSMG                                        AVSRSGGSTY                                    AATKSNTTAYRLSFDY                              16
  6                  SMYRMG                                        VITRNGSSTY                                    TSGSSYLDAAHVYDY                               15
  7                  SMDPMA                                        AGSSTGRTTY                                    APYGANWYRDEYAY                                14
  8                  SRYPVA                                        VISSTGTSTY                                    NSQRTRLQDPNEYDY                               15
  9                  SNRNMG                                        GISWGGGSTR                                    EFGHNIATSSDEYDY                               15
  10                 NFYAMS                                        GVSRDGLTTL                                    VITGVWNKVDVNSRSYHY                            18
  11                 SPTAMG                                        HITWSRGTTR                                    STFLRILPEESAYTY                               15
  12                 DNYAMA                                        TIDWGDGGAR                                    ARQSRVNLDVARYDY                               15

*^a^IMGT positions 24--40 in the acceptor sdAb were replaced with the indicated sequence*.

*^b^IMGT positions 56--69 in the acceptor sdAb were replaced with the indicated sequence*.

*^c^IMGT positions 105--117 in the acceptor sdAb were replaced with the indicated sequence*.

*^d^IMGT positions 35--40 in the acceptor sdAb were replaced with the indicated sequence*.

*^e^IMGT positions 55--66 in the acceptor sdAb were replaced with the indicated sequence*.

*^f^IMGT positions 105--117 in the acceptor sdAb were replaced with the indicated sequence*.

Design and Construction of Synthetic Human V~H~/V~L~ sdAb Phage Display Libraries {#S2-3}
---------------------------------------------------------------------------------

Three phage-displayed sdAb libraries were constructed by *in vitro* randomization of the sdAb scaffolds VH428, VHB82~SS~ and VL383~SS~. Briefly, nondegenerate oligonucleotides spanning each sdAb were chemically synthesized using the phosphoramidite method (GeneArt/Life Technologies) and purified by HPLC. CDRs were randomized *via* incorporation of defined mixtures of trinucleotide phosphoramidite building blocks ([@B41]) during oligonucleotide synthesis. Oligonucleotides were assembled without amplification by Klenow fragment extension, gel purified using a GeneJET™ gel extraction kit (Thermo-Fisher, Waltham, MA, USA) according to the manufacturer's instructions, and resuspended in a total volume of 1 mL TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). Non-amplified library DNA was quantified by real-time PCR using Fast SYBR™ Green master mix (Thermo-Fisher), and a StepOnePlus™ real-time PCR system (Thermo-Fisher), then approximately 232--1,069 ng (4.3 × 10^11^ to 1.5 × 10^12^ molecules) of DNA was PCR-amplified with Phusion^®^ high-fidelity DNA polymerase (Thermo-Fisher) using M13F and M13R primers (sequences in Table S1 in Supplementary Material), gel purified using a GeneJET™ gel extraction kit, then digested and ligated between the *Nco*I and *Not*I sites of the phagemid vector pMED1 ([@B42]). *Escherichia coli* TG1 cells were transformed with the ligation products by electroporation, yielding final library sizes between 1.0 × 10^10^ and 2.3 × 10^10^ independent transformants, ≥95% of which carried V~H~/V~L~ sdAb inserts as shown by colony PCR.

Antibodies, Proteins and Reagents {#S2-4}
---------------------------------

Recombinant human CEACAM6 (residues 145--232) and mouse GITR (residues 20--153) ectodomains were produced by transient transfection of HEK293-6E cells as previously described ([@B43]). HSA was from Sigma-Aldrich (St. Louis, MO, USA; Cat. No. A9511). Recombinant human CTLA4 ectodomain (residues 1--162) was from Sino Biological (Beijing, China; Cat. No. 11159-H08H). *E. coli* 0157:H7 intimin (residues 658--934) fused C-terminally to maltose-binding protein (MBP-intimin) was from GenScript (Piscataway, NJ, USA). Horseradish peroxidase-conjugated antibodies used in ELISA (mouse anti-M13, Cat. No. 27942101; mouse anti-c-Myc, Cat. No. 11814150001; rabbit anti-6 × His, Cat. No. A190-114P) were from GE Healthcare (Piscataway, NJ, USA), Bethyl Laboratories (Montgomery, TX, USA) and Roche Diagnostics (Basel, Switzerland), respectively. M13K07 helper phage was from New England BioLabs (Ipswich, MA, USA) and M13K07ΔpIII hyper phage was from Progen Biotechnik (Heidelberg, Germany).

Isolation of Antigen-Specific Human V~H~/V~L~ sdAbs by Panning {#S2-5}
--------------------------------------------------------------

Phage particles displaying monovalent V~H~/V~L~ sdAbs were prepared by rescue of the three synthetic human V~H~/V~L~ sdAb phagemid libraries with M13K07 helper phage as previously described ([@B42]). Briefly, 2 × YT broth (4 L) containing 1% (w/v) glucose and 100 µg/mL ampicillin was inoculated with 1 mL phagemid-bearing *E. coli* TG1 cells (7.3 × 10^10^ to 1.6 × 10^11^) and grown at 37°C with 250 rpm shaking to an OD~600~ of 0.5. Phagemid-bearing cells were superinfected with M13K07 helper phage at a multiplicity of infection of 20:1 at 37°C for 30 min with no shaking, then pelleted and resuspended in 6 L of 2 × YT broth containing 100 µg/mL ampicillin and 50 µg/mL kanamycin. The next day, phage particles were purified from bacterial supernatants using two rounds of polyethylene glycol precipitation; neither heat treatment nor filtration steps were used to remove residual bacterial cells. For panning, 5 µg of each protein in 35 µL phosphate-buffered saline (PBS), pH 7.4, was adsorbed overnight at 4°C in wells of NUNC MaxiSorp™ 96-well microtiter plates (Thermo-Fisher). The next day, wells were blocked with 200 µL PBS containing either 2% (w/v) bovine serum albumin (BSA) or 2% (w/v) skim milk for 1 h at 37°C, then rinsed 3 × with PBS. Approximately 5 × 10^11^ infective library phage particles (5 × 10^12^ virions) were added to wells in 100 µL of PBS containing 1% BSA or skim milk and 0.1% (v/v) Tween-20 for 2 h at room temperature. The blocking protein (BSA and skim milk) was switched in alternate rounds of panning, except for panning on HSA in which only skim milk was used. Wells were washed 5 × with PBS containing 0.1% Tween-20, 2 × with PBS and then bound phage were eluted for 10 min with 50 µL of 100 mM triethylamine, neutralized with 50 µL 1 M Tris-HCl, pH 7.5, and used to reinfect exponentially growing *E. coli* TG1 cells. The cultures were superinfected with M13K07 helper phage. The next day, amplified phage were purified by polyethylene glycol precipitation from 10 mL overnight cultures and used in subsequent panning rounds. After four or five rounds of selection, antigen-specific V~H~- or V~L~-displaying phage clones were identified by their binding in polyclonal and monoclonal phage ELISA as previously described ([@B42]).

Selection for Monomeric and Expressible Human V~H~/V~L~ sdAbs by Panning {#S2-6}
------------------------------------------------------------------------

Phage particles displaying monovalent V~H~/V~L~ sdAbs were prepared by rescue of phagemid libraries with M13K07 helper phage as described above. Phage particles displaying multivalent V~H~/V~L~ sdAbs on all copies of pIII were prepared as described above, except that: (i) smaller volumes (100 mL) of 2 × YT broth were inoculated with 1 mL phagemid-bearing *E. coli* TG1 cells, (ii) phagemid libraries were rescued with M13K07ΔpIII hyper phage at a multiplicity of infection of 10:1, and (iii) the final overnight culture volume was 150 mL of 2 × YT broth.

For panning, 5 µg of either protein A (for the VHB82~SS~ library; Thermo-Fisher) or protein L (for the VL383~SS~ library; Thermo-Fisher) in 50 µL PBS, pH 7.4, was adsorbed overnight at 4°C in wells of NUNC MaxiSorp™ 96-well microtiter plates. The next day, wells were blocked with 300 µL PBS containing either 2% BSA or skim milk for 1 h at 37°C, then rinsed 1 × with PBS. Approximately 10^11^ infective library phage particles (10^12^ virions) were added to wells in 100 µL of PBS containing 1% skim milk and 0.1% Tween-20 for 2 h at room temperature. Wells were washed 5 × with PBS containing 0.1% Tween-20, 2 × with PBS and then bound phage were eluted for 10 min with 50 µL of 100 mM triethylamine, neutralized with 50 µL 1 M Tris-HCl, pH 7.5, and used to reinfect exponentially growing *E. coli* TG1 cells. The cultures were superinfected with either M13K07 helper phage or M13K07ΔpIII hyper phage. The next day, amplified phage were purified by polyethylene glycol precipitation from 10 mL overnight cultures and used in subsequent panning rounds. After three rounds of selection, pools of sdAb-phage (either phage bound by and eluted from protein A/L, or phage amplified from overnight cultures) were interrogated using next-generation DNA sequencing (NGS) as described below.

Soluble V~H~/V~L~ Protein Expression {#S2-7}
------------------------------------

Monomeric V~H~/V~L~ sdAbs bearing C-terminal 6 × His and c-Myc tags were expressed from overnight cultures of *E. coli* TG1 cells grown in 250 mL to 1 L of 2 × YT broth under IPTG (isopropyl β-[D]{.smallcaps}-1-thiogalactopyranoside) induction, then extracted from periplasmic space by osmotic sucrose shock and purified by immobilized metal affinity chromatography as previously described ([@B42]). For small-scale expression screening, 5 mL overnight cultures were grown as above, lysed using FastBreak™ reagent (Promega, Madison, WI, USA) and sdAbs purified using PureProteome™ nickel magnetic beads (EMD Millipore, Billerica, MA, USA). Expression yields from 5 mL cultures were determined using the Bradford protein assay (Bio-Rad, Hercules, CA, USA) as per manufacturer's instructions with a V~H~H sdAb of known concentration as the protein standard. Titration ELISAs using soluble V~H~/V~L~ sdAbs were performed as previously described ([@B42], [@B44], [@B45]), using either anti-6 × His or anti-c-Myc secondary antibodies to detect binding.

Size Exclusion Chromatography (SEC) and SEC with Multiangle Light Scattering (MALS) {#S2-8}
-----------------------------------------------------------------------------------

Size exclusion chromatography analyses of monomeric V~H~/V~L~ sdAbs were conducted using a Superdex™ 75 GL column (GE Healthcare) connected to an ÄKTA FPLC protein purification system (GE Healthcare) as previously described ([@B42]). UPLC-SEC-MALS analyses of V~H~/V~L~ sdAbs were conducted essentially as previously described ([@B39]) using an Acquity BEH-125 column (Waters, Milford, MA) connected to an Acquity UPLC H-Class Bio system (Waters) with miniDAWN™ MALS detector and Optilab^®^ UT-rEX™ refractometer (Wyatt Technology, Santa Barbara, CA, USA). V~H~/V~L~ sdAbs (10--20 µg) were injected at 30°C in a mobile phase consisting of calcium- and magnesium-free DPBS (GE Healthcare) at a flow rate of 0.4 mL/min. Weighted average molecular mass (*M*~MALS~) was calculated using a protein concentration determined using A~280~ from the PDA detector with extinction coefficients calculated from amino acid sequences. Data were processed using ASTRA 6.1 software (Wyatt).

Surface Plasmon Resonance (SPR) {#S2-9}
-------------------------------

All monomeric human V~H~/V~L~ sdAbs were SEC-purified and buffer-exchanged into HBS-EP buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) surfactant P20, pH 7.4) prior to SPR analyses. All SPR analyses were performed on a Biacore™ 3000 instrument (GE Healthcare) at a temperature of 25°C. Briefly, proteins (CEACAM6, 370 resonance units (RUs); HSA, 1614 RUs; GITR, 796 RUs; MBP-intimin, 1536 RUs) were immobilized *via* amine coupling on research-grade CM5 sensor chips (GE Healthcare) in 10 mM acetate buffer, pH 4.0, according to the manufacturer's instructions. V~H~/V~L~ sdAbs were injected at concentrations ranging from 1 nM to 10 µM, at flow rates of 20--50 µL/min and with contact time between 120 s and 300 s, then allowed to dissociate for 7--10 min. All surfaces were regenerated using 10 mM glycine, pH 1.5. Ethanolamine-blocked flow cells served as reference surfaces. The data were fitted to a 1:1 interaction model and binding affinities (*K*~D~s) and/or kinetic parameters were determined either by steady-state analysis or by multicycle kinetic analysis using BIAevaluation 4.1 software (GE Healthcare).

Surface plasmon resonance analyses of two V~L~ sdAbs (VL~SS~-2 and VL~SS~-5) against MBP-intimin were conducted as described above, except that 234 RUs of MBP-intimin were immobilized on a research-grade C1 sensor chip (GE Healthcare) *via* amine coupling in 10 mM acetate buffer, pH 4.5, according to the manufacturer's instructions. These two V~L~ sdAbs were injected in HBS-EP buffer containing either 150 or 500 mM NaCl with an extended contact time (600 s).

Protein Turbidity Assays {#S2-10}
------------------------

V~H~/V~L~ sdAb samples (0.2 mL) in 1.5 mL microcentrifuge tubes were heated to 85°C in a heating block for 10 min, then allowed to cool to room temperature for 30 min. Absorbance at 360 nm was measured pre- and post-heat treatment in a quartz NanoQuant Plate™ (Tecan, Männedorf, Switzerland) using an Infinite^®^ M200 PRO microplate reader (Tecan). V~H~/V~L~ sdAb concentrations were adjusted to 0.25 mg/mL in PBS prior to analysis.

Thermal Shift Assays {#S2-11}
--------------------

V~H~/V~L~ sdAb samples (45 µL) in 96-well thin-wall optical plates (Bio-Rad) were mixed with 5 µL SYPRO^®^ Orange (diluted 1:100 from 5,000 × stock; Life Technologies, Carlsbad, CA, USA) and sealed with optical quality sealing tape (Bio-Rad). Using an iQ™ 5 real-time PCR system (Bio-Rad), a temperature ramp of 1°C/min was applied and thermal unfolding was monitored by measuring fluorescence at 0.5°C intervals as previously described ([@B46], [@B47]). The wavelengths for excitation and emission were 490 and 575 nm, respectively. Melting temperatures (*T*~m~s) were calculated as the temperature at which the maximum rate of change in fluorescent signal (d(RFU)/d*t*) was achieved. V~H~/V~L~ sdAb concentrations were adjusted to 1 mg/mL in PBS prior to analysis.

Circular Dichroism {#S2-12}
------------------

*T*~m~s were also determined by circular dichroism as previously described ([@B39], [@B40]). Ellipticity of V~H~/V~L~ sdAbs (100 µg/mL) was measured at wavelengths between 205 and 210 nm in 100 mM sodium phosphate buffer, pH 7.4. Ellipticity measurements were normalized to a percentage scale and then *T*~m~s were determined by plotting percent folded versus temperature and fitting the data to a Boltzmann distribution.

Next-Generation DNA Sequencing {#S2-13}
------------------------------

V~H~/V~L~ sdAb libraries were interrogated using an Illumina MiSeq instrument as described previously ([@B44], [@B45], [@B48]). Amplicons for NGS were prepared using FR1- and FR4-specific barcoded primers (sequences in Table S1 in Supplementary Material) using as template either phagemid DNA (\~10 ng) or phage virions (\~10^6^ particles).

Statistical Analyses {#S2-14}
--------------------

Descriptive statistics (mean, median) were used to describe datasets as described in figure legends. No inferential statistical tests were used.

Results {#S3}
=======

Antigen-specific human autonomous V~H~/V~L~ sdAbs do not exist in nature, and are most commonly isolated from synthetically randomized *in vitro* display libraries. These molecules are notoriously unstable and aggregation prone ([@B4]), which probably negatively impacts the selection of antigen-specific binders from synthetic V~H~/V~L~ sdAb libraries. In an effort to mitigate these factors, we attempted to identify ultra-stable V~H~/V~L~ sdAb scaffolds upon which we could construct highly diverse, stability-enhanced phage-displayed V~H~/V~L~ sdAb libraries designed to yield soluble and thermostable antigen-specific human sdAbs.

Biophysical Stability Assessment of Wild-Type Human V~H~/V~L~ sdAb Scaffolds {#S3-1}
----------------------------------------------------------------------------

The *T*~m~s and aggregation tendencies of 22 potential V~H~ sdAb scaffolds and 18 potential V~L~ sdAb scaffolds were determined by circular dichroism and SEC (Tables S2 and S3 in Supplementary Material). Five V~H~ and five V~L~ sdAb scaffolds as well as their disulfide-stabilized equivalents (Table [1](#T1){ref-type="table"}) were selected as the most promising candidates for library construction based on: (i) primarily monomeric folding, (ii) high thermostability with reversible thermal unfolding, and (iii) reasonable expression yields (\>1 mg/L) from overnight *E. coli* TG1 cultures. As reported previously ([@B39], [@B40]), incorporation of a disulfide linkage spanning IMGT positions 54--78 increased the *T*~m~ of each scaffold by \~5--20°C but also had unpredictable effects on expression yields.

Tolerance of Human V~H~/V~L~ sdAb Scaffolds to CDR Modification {#S3-2}
---------------------------------------------------------------

As a preliminary investigation into which of the 20 V~H~/V~L~ sdAb scaffolds might best tolerate library randomization, we grafted 12 sets of exogenous CDRs (Table [2](#T2){ref-type="table"}) into each scaffold and assessed the resulting molecules' expression level (Bradford assay), aggregation tendency (SEC-MALS), *T*~m~ (thermal shift assay), and ability to refold after thermal denaturation (turbidity assay). For V~L~ sdAb scaffolds, the 12 sets of exogenous CDRs were derived from non-antigen-specific human V~L~ sdAbs isolated from previously constructed libraries with expression yields ≥10 mg/L and for V~H~ sdAb scaffolds, the 12 sets of exogenous CDRs were selected from either human V~H~ sdAbs of unknown antigen specificity isolated from previously constructed libraries or camelid V~H~H sdAbs with expression yields ≥3 mg/L.

The V~L~ sdAb scaffolds yielding the best-expressing CDR-shuffled variants were VL383~SS~, VL325~SS~ and VL335~SS~ (Figure [1](#F1){ref-type="fig"}A). CDR-shuffled variants of VL383~SS~ and VL325~SS~ were primarily monomeric by SEC-MALS, while CDR-shuffled variants of VL335~SS~ showed some tendency to aggregate (Figure [1](#F1){ref-type="fig"}C). All three of these V~L~ sdAb scaffolds, especially VL325~SS~, yielded CDR-shuffled variants with high *T~m~*s (Figure [1](#F1){ref-type="fig"}E); however, many CDR-shuffled variants of VL325~SS~ showed significant turbidity upon heat denaturation (Figure [1](#F1){ref-type="fig"}G), reflecting their inability to refold as soluble monomers. The V~H~ sdAb scaffolds yielding the best-expressing CDR-shuffled variants were VH420, VH428, VHB82, VHB82~SS~, and VHM81~SS~ (Figure [1](#F1){ref-type="fig"}B). CDR-shuffled variants of all five of these V~H~ sdAb scaffolds were similarly monomeric (Figure [1](#F1){ref-type="fig"}D) but as expected, the two disulfide-stabilized sdAb scaffolds (VHB82~SS~ and VHM81~SS~) yielded CDR-shuffled variants with higher *T~m~*s (Figure [1](#F1){ref-type="fig"}F). Similar proportions of the CDR-shuffled variants of all five V~H~ sdAb scaffolds showed minor turbidity upon heat denaturation (Figure [1](#F1){ref-type="fig"}H). On the basis of these data, we selected one V~L~ sdAb scaffold (VL383~SS~) and two V~H~ sdAb scaffolds (VH428 and VHB82~SS~) for library construction, reflecting a balance of their tolerance to CDR modification as well as their differing CDR3 lengths and germline gene rearrangements.

![Biophysical stability assessment of complementarity-determining region (CDR)-shuffled human V~H~/V~L~ single-domain antibody (sdAb) variants. **(A,B)** Expression yields of CDR-shuffled V~L~ **(A)** and V~H~ **(B)** sdAbs from 5 mL overnight cultures, as determined by Bradford assay. Two outliers (VL382 + CDR set 9, expression yield 467.7 µg/mL and VH428~SS~ + CDR set 2, 356.4 µg/mL) are indicated by green triangles. **(C,D)** Aggregation tendencies of CDR-shuffled V~L~ **(C)** and V~H~ **(D)** sdAbs, as determined by SEC-MALS. **(E,F)** Melting temperatures (*T~m~*s) of CDR-shuffled V~L~ **(E)** and V~H~ **(F)** sdAbs, as determined by thermal shift assay. **(G,H)** Turbidity upon thermal denaturation of CDR-shuffled V~L~ **(G)** and V~H~ **(H)** sdAbs, as measured by spectrophotometry at 360 nm wavelength. Dashed lines represent the range of turbidity measurements for unheated V~H~/V~L~ sdAbs. The aggregation tendencies, *T~m~*s and turbidities of CDR-shuffled variants of VH429 were not characterized due to inadequate expression yields. Horizontal lines represent mean **(C,D,G,H)** or median **(A,B,E,F)** values and wild-type V~H~/V~L~ sdAbs with unmodified CDRs are shown in red. Open and solid circles represent V~H~/V~L~ sdAbs with, or without, a stabilizing exogenous disulfide linkage. The number of data points in each panel reflects whether the experiment was conducted in singlicate **(C,E)** or duplicate **(A,B,D,F--H)** and for panels **(C--H)**, whether the CDR-shuffled variant expressed sufficiently for analysis.](fimmu-08-01759-g001){#F1}

Design and Construction of Phage-Displayed Human V~H~/V~L~ sdAb Libraries {#S3-3}
-------------------------------------------------------------------------

Three synthetic sdAb libraries (VL383~SS~, VH428, and VHB82~SS~) were constructed by limited *in vitro* randomization of the CDRs of these V~H~/V~L~ sdAb scaffolds and cloning of the resulting DNA into the pMED1 phagemid vector (Figures [2](#F2){ref-type="fig"}A,B). CDR3 length was varied in each library (Figures [2](#F2){ref-type="fig"}A,D; VL383~SS~ library: 8, 9, or 10 residues; VH428 and VHB82~SS~ libraries: 10, 12, 14, 16, 18, 20, or 22 residues) while CDR1 and CDR2 lengths were constant. The major technical advances of these over our previously described phage-displayed synthetic human V~H~/V~L~ sdAb libraries ([@B12], [@B21], [@B31]) were (i) trinucleotide mutagenesis allowed for incorporation of defined mixtures of amino acids at each randomization position, based on alignments of human and llama antibodies with additional bias toward solubility-promoting residues (Asp, Glu) and against undesirable residues (Asn, Cys, and Met) and stop codons (Figures [2](#F2){ref-type="fig"}B,C; Figure S2 in Supplementary Material) and (ii) near-complete randomization of all three CDRs of each V~H~/V~L~ sdAb scaffold resulted in much higher sequence diversity for the vast majority of library molecules (Figure [2](#F2){ref-type="fig"}E). All three V~H~/V~L~ sdAb libraries were transformed into *E. coli* TG1 cells, yielding final library sizes (1.0--2.3 × 10^10^ independent transformants) that, as expected, vastly under-sampled theoretical library diversity (VL383~SS~: 2.9 × 10^13^ unique sequences; VHB82~SS~: 2.3 × 10^33^ unique sequences; VH428: 2.3 × 10^35^ unique sequences). At this stage, prior to helper phage rescue, no major clonality biases or deviations from library design were observed (data not shown).

![Design and construction of the VL383~SS~, VH428, and VHB82~SS~ synthetic human V~H~/V~L~ single-domain antibody (sdAb) libraries. **(A)** Design of the human V~H~/V~L~ sdAb libraries. The parental V~H~/V~L~ sdAb sequence is shown at top with IMGT numbering. Intradomain disulfide linkage-forming cysteine residues at positions 54 and 78 are shown in magenta. Randomization positions are highlighted in either red (no length polymorphism) or green (length polymorphism). Arabic numerals indicate the codon mixture (X1, X2, X3, X4, or X5) incorporated at each randomization position. **(B)** Expected amino acid frequencies at V~H~/V~L~ sdAb library randomization positions. **(C)** Observed amino acid frequencies at V~H~/V~L~ sdAb library randomization positions, measured from phagemid DNA isolated from *Escherichia coli* TG1 cells. Crossed-out cells indicate a frequency of \<0.1%. **(D)** CDR3 length distributions of the V~H~/V~L~ sdAb libraries. **(E)** Degree of randomized sequence diversity (Levenshtein distance, or number of amino acid changes with respect to the parental scaffold) in the V~H~/V~L~ sdAb libraries. Analyses shown in **(C--E)** are representative of 7.7 × 10^4^ to 7.9 × 10^5^ sequences per library.](fimmu-08-01759-g002){#F2}

Isolation and Characterization of Antigen-Specific Human V~H~/V~L~ sdAbs {#S3-4}
------------------------------------------------------------------------

All three V~H~/V~L~ sdAb libraries were rescued with M13K07 helper phage and panned for four or five rounds against five model antigens (CEACAM6, CTLA4, GITR, HSA, and MBP-intimin). All library pannings were performed in duplicate by two independent operators at the same time and using the same materials, except for panning against MBP-intimin, in which panning was done in triplicate. High attrition rates of V~H~/V~L~ sdAbs showing false positive binding either as sdAb-phage or as soluble sdAb proteins (VL383~SS~: 53% attrition; VH428: 69% attrition; VHB82ss: 71% attrition; Table [3](#T3){ref-type="table"}) resulted in a final yield of 20 unique antigen-specific V~H~/V~L~ sdAbs against four targets. Of the 15 library-target screens we conducted, eight (53%) yielded at least one antigen-specific V~H~/V~L~ sdAb (four screens yielded one sdAb, two screens yielded two sdAbs, one screen yielded three sdAbs, and two screens yielded five sdAbs). Most of the recovered sdAbs were monomeric (Figure [3](#F3){ref-type="fig"}A; Table [4](#T4){ref-type="table"}; Figure S3 in Supplementary Material), thermostable (Figure [3](#F3){ref-type="fig"}B; Table [4](#T4){ref-type="table"}), and had affinities for antigen ranging from 5 nM to \~12 μM (Figures [3](#F3){ref-type="fig"}C,D; Table [4](#T4){ref-type="table"}). One notable exception was the α-GITR V~H~ sdAb VHB82~SS~-6, whose elution volume by SEC suggested it existed in solution as a strict dimer (Figure [3](#F3){ref-type="fig"}A). Stable homodimerization has previously been reported for several human V~H~ sdAbs and was critical for antigen binding ([@B49]--[@B52]); this phenomenon is distinct from the general tendency of some V~H~ domains to forms soluble aggregates. Antigen-specific V~H~/V~L~ sdAbs isolated from all three libraries had aggregation tendencies and thermostabilities reflective of the parental V~H~/V~L~ sdAb scaffold from which they were derived, but generally poorer expression yields (Figure [4](#F4){ref-type="fig"}A). Reproducibility in the selection of specific sdAb sequences from the libraries was modest, with only 45% (9/20) of antigen-specific V~H~/V~L~ sdAbs recovered by both operators (Figure [4](#F4){ref-type="fig"}B) and no apparent connection between antigen-binding affinity and consistency of isolation.

###### 

Attrition rates of human V~H~/V~L~ single-domain antibodies (sdAbs) through isolation and characterization.

  Library                                        Target      No. of binding sdAbs              
  ---------------------------------------------- ----------- ---------------------- ---------- ---
  VL383~SS~                                      CEACAM6     1                      1          1
  CTLA4                                          4           0                                 
  GITR                                           0                                             
  HSA                                            2           0                                 
  MBP-intimin[^a^](#tfn9){ref-type="table-fn"}   3, 5        2, 4                   2, 4       
                                                 15 (100%)   7 (47%)                7 (47%)    
  VH428                                          CEACAM6     3                      3          3
  CTLA4                                          3           0                                 
  GITR                                           4           0                                 
  HSA                                            2           0                                 
  MBP-intimin                                    4           2                      2          
                                                 16 (100%)   5 (31%)                5 (31%)    
  VHB82~SS~                                      CEACAM6     5                      5          5
  CTLA4                                          9           0                                 
  GITR                                           5           1                      1          
  HSA                                            6           3                      1          
  MBP-intimin                                    3           2                      1          
                                                 28 (100%)   11 (39%)               8 (29%)    
                                                                                               
  Total                                          59 (100%)   23 (39%)               20 (34%)   

*^a^Double entries reflect two independent isolation attempts*.

![Properties of selected antigen-specific single-domain antibodies (sdAbs) isolated from the VL383~SS~, VH428, and VHB82~SS~ synthetic human V~H~/V~L~ sdAb libraries. The single highest affinity sdAb against each target is shown, except for MBP-intimin, where VL~SS~-3 is shown instead of VL~SS~-4 or VL~SS~-5 because of better fit to a 1:1 binding model. **(A)** Size exclusion chromatography (SEC) profiles of representative antigen-specific human V~H~/V~L~ sdAbs. Arrows show molecular mass standards, from left to right: thyroglobulin (670 kDa), gamma globulin (158 kDa), ovalbumin (44 kDa), myoglobin (17 kDa), and vitamin B12 (1.35 kDa). **(B)** Thermal unfolding of representative antigen-specific V~H~/V~L~ sdAbs as determined by circular dichroism. Replicate unfolding curves are shown in red and blue; the sdAbs were then cooled to room temperature and remelted (shown in orange and green). **(C)** Titration ELISA of representative antigen-specific V~H~/V~L~ sdAbs. Horseradish peroxidase mouse anti-c-Myc secondary antibody (clone 9E10, diluted 1:3,000) was used for detection. **(D)** Binding of antigen-specific V~H~/V~L~ sdAbs to cognate antigen by SPR. Each antigen was immobilized on a CM5 sensor chip using amine coupling, then the indicated V~H~ or V~L~ sdAb was flowed over the surface at concentrations ranging from 25 to 1,000 nM (α-CEACAM6 VHB82~SS~-2), 25 to 500 nM (α-GITR VHB82~SS~-6), 2.5 to 50 nM (α-HSA VHB82~SS~-7), or 62.5 to 2,500 nM (α-MBP-intimin VL383~SS~-3). Black lines show data and red lines show fits.](fimmu-08-01759-g003){#F3}

###### 

Properties of antigen-specific single-domain antibodies (sdAbs) isolated from the phage-displayed synthetic human V~H~/V~L~ libraries.

  Target        V~H~/V~L~ sdAb   Expression yield (mg/L)   Monomer (%)                           *T*~m~ (°C)                               *K*~D~ (nM)
  ------------- ---------------- ------------------------- ------------------------------------- ----------------------------------------- ---------------------------------------
  CEACAM6       VL383~SS~-1      18.4                      \>95                                  76.9                                      454[^a^](#tfn10){ref-type="table-fn"}
  VH428-1       3.4              \>95                      57.6                                  2,180[^a^](#tfn10){ref-type="table-fn"}   
  VH428-2       3.6              \>95                      61.5                                  1,230[^b^](#tfn11){ref-type="table-fn"}   
  VH428-3       1.9              \>95                      52.9                                  290[^b^](#tfn11){ref-type="table-fn"}     
  VHB82~SS~-1   6.4              \>95                      81.4                                  638[^b^](#tfn11){ref-type="table-fn"}     
  VHB82~SS~-2   18.8             \>95                      75.1                                  245[^b^](#tfn11){ref-type="table-fn"}     
  VHB82~SS~-3   5.4              \>95                      72.5                                  2,730[^a^](#tfn10){ref-type="table-fn"}   
  VHB82~SS~-4   3.2              80.0                      68.3                                  1,070[^a^](#tfn10){ref-type="table-fn"}   
  VHB82~SS~-5   2.4              \>95                      71.9                                  2,200[^a^](#tfn10){ref-type="table-fn"}   
  GITR          VHB82~SS~-6      7.2                       0[^e^](#tfn14){ref-type="table-fn"}   81.4                                      196[^b^](#tfn11){ref-type="table-fn"}
  HSA           VHB82~SS~-7      8.0                       \>95                                  67.7                                      5[^b^](#tfn11){ref-type="table-fn"}
  MBP-intimin   VL383~SS~-2      2.0                       \>95                                  69.6                                      905^b,c^
  VL383~SS~-3   0.2              83.4                      65.1                                  395[^b^](#tfn11){ref-type="table-fn"}     
  VL383~SS~-4   1.2              88.7                      65.3                                  227[^b^](#tfn11){ref-type="table-fn"}     
  VL383~SS~-5   3.7              94.6                      74.2                                  252^b,c^                                  
  VL383~SS~-6   9.9              \>95                      76.6                                  7,470[^a^](#tfn10){ref-type="table-fn"}   
  VL383~SS~-7   8.0              \>95                      76.7                                  11,500^a,d^                               
  VH428-4       0.1              \>95                      58.9                                  2,590[^b^](#tfn11){ref-type="table-fn"}   
  VH428-5       0.1              \>95                      n.d.                                  4,430[^a^](#tfn10){ref-type="table-fn"}   
  VHB82~SS~-8   8.0              72.5                      69.3                                  5,230[^a^](#tfn10){ref-type="table-fn"}   

*^a^Determined using steady-state analysis at 25°C*.

*^b^Determined using multicycle kinetic analysis and fitting to a 1:1 binding model at 25°C*.

*^c^Antigen was immobilized on a C1 sensor chip, evidence of complex binding*.

*^d^K~D~ is an estimate only due to lack of curvature in the steady-state plot*.

*^e^Size exclusion chromatography elution volume suggests VHB82~SS~-6 is a strict dimer*.

*n.d., not determined*.

![Properties of all antigen-specific single-domain antibodies (sdAbs) isolated from the VL383~SS~, VH428 and VHB82~SS~ synthetic human V~H~/V~L~ sdAb libraries. **(A)** Expression yields (as measured by spectrophotometry at 280 nm), *T~m~*s (as determined by circular dichroism), and aggregation tendencies (as determined by size exclusion chromatography) of antigen-specific V~H~/V~L~ sdAbs isolated from the libraries in comparison to the parental scaffold from which they were derived (shown in red). **(B)** Interoperator reproducibility in isolating individual V~H~/V~L~ sdAb sequences.](fimmu-08-01759-g004){#F4}

Evaluation of Stability-Sequence Diversity Tradeoffs in Human V~H~/V~L~ sdAb Libraries {#S3-5}
--------------------------------------------------------------------------------------

To better understand potential constraints on the CDR sequences of monomeric and stable human V~H~/V~L~ sdAbs, we examined the effects of stability selection (three rounds of protein A or L selection followed by amplification of the eluted phage overnight in *E. coli* TG1 cells; Figure [5](#F5){ref-type="fig"}) on randomized sequence diversity of two V~H~/V~L~ sdAb libraries (VL383~SS~ and VHB82~SS~). We performed this experiment in duplicate using either phage particles displaying monovalent sdAb (rescued with M13K07 helper phage; simultaneous expression of pIII from helper phage and pIII-sdAb from phagemid) or phage particles displaying multivalent sdAb (rescued with M13K07ΔpIII hyper phage; only pIII-sdAb expressed from phagemid). Out-of-frame and/or stop-codon-encoding V~H~/V~L~ sdAb clones were rare in both libraries ("Library Cells"), but rose substantially in frequency upon phage rescue ("Library Phage") and upon amplification in *E. coli* ("Amplification in *E. coli*"), suggesting a growth advantage for non-sdAb expressing cells over sdAb-expressing ones (Figures [5](#F5){ref-type="fig"}A,B); this phenomenon was mitigated somewhat using hyper phage rescue. After three rounds of protein A/L selection and overnight amplification in *E. coli* with helper phage rescue, there were clear clonal biases observed in the resulting populations of sdAb-phage (Figures [5](#F5){ref-type="fig"}C,D). Using an arbitrary frequency cutoff (0.00006% for VL383~SS~ and 0.00004% for VHB82~SS~; sdAbs at frequencies greater than these cutoffs were not present in any other dataset) to identify unique sdAb sequences enriched by stability selection, we found that different sdAb clones were selected in the two replicate pannings, although both sets of sdAbs were heavily biased toward the parental V~H~/V~L~ sdAb scaffold's CDR3 length (9 residues for the VL383~SS~ library and 10 residues for the VHB82~SS~ library, which is the shortest CDR3 length possible in the library design and the nearest to the VHB82~SS~ scaffold's CDR3 length of 6 residues; Figure S4 in Supplementary Material). However, stability selection reproducibly yielded V~H~/V~L~ sdAbs with biased CDR amino acid composition (Figures [5](#F5){ref-type="fig"}E,F; Figures S5 and S6 in Supplementary Material). In order of magnitude, stability biases in the VL383~SS~ library favored Asp, His, Pro, Ser and Thr and disfavored aromatic (Phe, Trp, Tyr) and hydrophobic (Ile, Leu, Val) residues. Similarly, stability biases in the VHB82~SS~ library favored Asp, His, Pro, and Gln and disfavored aromatic (Phe, Trp, Tyr) and hydrophobic (Ile, Leu, Val) residues. These biases were especially acute at the C-terminus of CDR1 and N-terminus of CDR2, both of which flank FR2. Identical molecular signatures were observed to a lesser degree in the pools of all sdAb-phage (irrespective of frequency or mono- vs. multivalent display format) subjected to three rounds of stability selection (Figures S7 and S8 in Supplementary Material) as well as in the pools of sdAb-phage after phage rescue and eluted from protein A/L (data not shown), suggesting a common ontogeny.

![Impact of stability selection on human V~H~/V~L~ single-domain antibody (sdAb) library sequence diversity. After transformation of *Escherichia coli* TG1 cells with phagemid DNA, phage were rescued by superinfection of overnight cultures with M13K07 helper phage or M13K07ΔpIII hyper phage. The purified sdAb-displaying phage were bound and eluted from protein A (VHB82~SS~ library) or protein L (VL383~SS~ library), then amplified by reinfection of *E. coli* TG1 cells. Three rounds of panning were performed, and V~H~/V~L~ sdAb sequences were interrogated by NGS at the stage of rescued phage, phage eluted after a single round of protein A/L selection, and phage amplified after the final round of panning. **(A,B)** Proportion of functional sdAb sequences (in-frame ORF, no stop codons) observed in V~L~ **(A)** and V~H~ **(B)** library phage and panning outputs. **(C,D)** Clonality of V~L~ **(C)** and V~H~ **(D)** library phage and panning outputs. **(E,F)** Complementarity-determining region (CDR) amino acid composition of enriched V~L~ **(E)** and V~H~ **(F)** sdAb clones after three rounds of stability selection. Crossed-out cells indicate a frequency of \<0.1%. Analyses in **(A--F)** are representative of 7.7 × 10^4^ to 7.9 × 10^5^ sequences per sample.](fimmu-08-01759-g005){#F5}

Discussion {#S4}
==========

The starting point for this investigation was the observation that several of our previously described synthetic human V~H~/V~L~ sdAb libraries performed unpredictably ([@B12], [@B21], [@B31]), yielding monomeric antigen-specific binders against some targets but not others. Thus, we tested the hypothesis that these issues might be solved by: (i) building libraries on ultrastable V~H~/V~L~ sdAb scaffolds that maintain their biophysical properties upon CDR modification and (ii) randomizing the CDRs of the V~H~/V~L~ sdAb libraries more extensively using trinucleotide mutagenesis. A few general lessons became apparent during the course of these experiments. First, although V~H~/V~L~ sdAb scaffolds clearly vary in their tolerance to CDR modification, no "perfect" scaffold exists (i.e., some CDR-shuffled variants of every scaffold showed poor biophysical properties). Second, the trinucleotide mutagenesis approach used here was dramatically more effective at incorporating randomized sequence diversity in V~H~/V~L~ sdAb CDRs compared to the Kunkel mutagenesis ([@B21], [@B31]) and splicing by overlap extension PCR mutagenesis approaches using degenerate oligonucleotides ([@B12]) that we have used previously. Third, as we showed previously ([@B31]), incorporating a stabilizing exogenous disulfide linkage spanning IMGT positions 54--78 into V~H~/V~L~ sdAb libraries is clearly compatible with selection of antigen-specific binders, as 15/20 of the binders shown here bear this linkage. Finally, it is clearly possible, at least under some circumstance, to select monomeric, high-affinity binders from synthetic human V~H~/V~L~ sdAbs libraries, as evidenced by the α-HSA VH~SS~-7 sdAb (*K*~D~: 5 nM) reported here.

However, the more general issues afflicting synthetic human V~H~/V~L~ sdAb libraries (high attrition rates due to false positive binding, possibly caused by sdAb aggregation; inconsistency of isolation; variable expression yield and aggregation of isolated sdAbs) were not completely solved by using more stable V~H~/V~L~ scaffolds or building more diverse and non-degenerate libraries. The additional randomized sequence diversity we achieved by the use of trinucleotide mutagenesis is almost certainly negligible when compared to the theoretical size of the libraries, and massive undersampling may account at least in part for inconsistent isolation of sdAbs. Other potential solutions to the problem of undersampling include increasing throughput ([@B53]), use of V~H~/V~L~ sdAb-transgenic mice ([@B54], [@B55]) and use of *in vitro* VDJ recombination systems ([@B56]). Nonetheless, modest inter-operator reproducibility in isolating the same binders clearly demonstrates that antigen-specific human V~H~/V~L~ sdAbs are not always isolated even when they were present in the library. We currently have no understanding of the factors influencing the number of V~H~/V~L~ sdAb binders isolated, their affinities or biophysical properties, nor if these depend on the library, the target antigen quality or composition, or the panning methodology. One possibility, for example, is that the numbers of input library sdAb-phage used here, the target antigen surface size and density, and/or the numbers of eluted phage amplified from each round of selection were inadequate to consistently recover very rare sdAb specificities that may be present in the libraries. These factors could be investigated empirically in future studies.

It is virtually certain that some of the challenges of human synthetic V~H~/V~L~ sdAbs relate to fundamental tradeoffs between stability and sequence diversity. There is no necessary reason why rare autonomous rearranged human V~H~/V~L~ sdAbs should be compatible with any CDR sequence; rather, it should be expected that these molecules rely chiefly on particular CDR sequences for their solubility and stability, given that human V~H~ and V~L~ domains have evolved to be paired with one another, occluding a hydrophobic surface between the two domains. We expect that such challenges are much less of a problem for protein domains that naturally exist as soluble monomers such as camelid and shark sdAbs and non-antibody scaffolds (e.g., FN3 and SH3 domains). Some camelid V~H~Hs rely on CDR residues for solubility as well ([@B57]), albeit likely to a lesser extent due to the presence of solubility-enhancing FR2 residues. One obvious explanation for the previously described bias toward negatively charged residues resulting in acidic overall pIs of V~H~/V~L~ sdAbs ([@B4], [@B12]), especially in CDR1 and CDR2 ([@B10], [@B11]), is that this may enhance solubility and aggregation resistance. The role of charge and negative charge in particular in solubilizing V~H~/V~L~ sdAbs with hydrophobic CDRs has been previously demonstrated ([@B58], [@B59]), and appears to be highly position and scaffold dependent ([@B4]). Bias in favor of His residues is less easy to explain, although its imidazole side chain may also have stabilizing and solubilizing effects near physiological pH ([@B60]). Notably, "camelized" human V~H~ sdAbs and human V~H~/V~L~ sdAbs selected *in vitro* to bear solubility-promoting FR substitutions ([@B9], [@B61]), may not be subject to the same stability-sequence diversity tradeoffs. We caution that although the growth advantages conferred by V~H~/V~L~ sdAbs with the most stable and soluble CDR sequences were most apparent using helper phage rescue of phagemid libraries, forcing pIII-sdAb expression using hyper phage rescue or by using phage (not phagemid) or yeast display systems would not be expected to circumvent the issue of bias; instead, it might be expected to result in immediate loss of a large population of V~H~/V~L~ sdAbs with poorly stable and soluble CDR sequences.

In conclusion, we have described three novel synthetic human V~H~/V~L~ sdAb libraries as well as antigen-specific binders against a variety of target antigens selected from these libraries. Future work will seek to better understand the constraints imposed on human V~H~/V~L~ sdAbs by stability-sequence diversity tradeoffs, and whether it is possible to circumvent them by *in vitro* engineering of human autonomous immunoglobulin variable domain folds. One possibility would be to identify and fix a minimal set of stability-enhancing CDR residues in human V~H~/V~L~ sdAb libraries, which might allow for more effective randomization of the remaining CDR positions. However, doing so without significant divergence from human germline IGHV sequences, increasing the risk of immunogenicity, may be very challenging.

Author Contributions {#S5}
====================

DK, HK, and JT isolated and characterized human V~H~/V~L~ sdAb scaffolds and conducted CDR-shuffling experiments and designed the libraries. JS conducted SEC-MALS experiments. ML, HK, and KH isolated and characterized antigen-specific sdAbs. ML and KH conceived and carried out stability selections and next-generation DNA sequencing analyses. QY, GH, and CRM designed, carried out, and analyzed surface plasmon resonance experiments. KH and GH made the figures and KH wrote the manuscript. All authors read and approved the final manuscript.

Conflict of Interest Statement {#S6}
==============================

JT and DK are inventors of US patents 8293233B2 and 9371371B2 as well as other patents and patent applications governing human V~H~/V~L~ sdAb scaffolds.

We gratefully acknowledge the excellent technical help of Camille Hebert-Martineau, Sonia Leclerc, Hongtao Qi, Ken Chan, Shannon Ryan, and Julie Champagne.

**Funding.** This work was supported by funding from the National Research Council Canada.

Supplementary Material {#S7}
======================

The Supplementary Material for this article can be found online at <http://www.frontiersin.org/articles/10.3389/fimmu.2017.01759/full#supplementary-material>.

###### 

Click here for additional data file.

[^1]: Edited by: Abdul Qader Abbady, Atomic Energy Commission of Syria, Syria

[^2]: Reviewed by: Serge Muyldermans, Vrije Universiteit Brussel, Belgium; Oscar R. Burrone, International Centre for Genetic Engineering and Biotechnology, Italy

[^3]: This is NRC-HHT publication number: 53364.

[^4]: Specialty section: This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
